ArticleJournal of neurochemistry2026
Altered Retinal Dopamine Homeostasis in Murine Models of Retinitis Pigmentosa.
Article in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Retinitis pigmentosa (RP) is a heterogeneous group of currently untreatable inherited retinal degenerations that share similar disease manifestations despite distinctive genetic causes. Dopamine (DA) is an important and tightly regulated catecholaminergic neurotransmitter required for multiple modulatory functions throughout the central nervous system, including the retina. Dysregulation of DA homeostasis has been reported during neurodegeneration, but how it is regulated in RP remains poorly understood. Here, we demonstrate that early RP is associated with marked dysregulation of the dopaminergic system using two distinct disease models, P23H and rd10 mice. We found increased DA levels in RP retinas collected from pre-weaned (P12), juvenile (P30), and adult (P60-90) mice by utilising ultra-high-performance liquid chromatography and matrix-assisted laser desorption/ionisation mass spectrometry. Consistently, DA levels were also elevated in the vitreous of P23H mice, where it likely diffuses from the retina. RP retinas additionally demonstrated higher levels of DA precursor l-3,4-dihydroxyphenylalanine (L-DOPA), as well as upregulated tyrosine hydroxylase gene expression, which suggests elevated DA synthesis. In parallel, we observed increased activity and expression of the catecholamine-metabolising enzyme catechol-O-methyltransferase (COMT) during retinal degeneration. Comparative tissue analysis with cortex, striatum, retina, and eye cup samples further highlighted COMT as a major contributor to catecholamine inactivation in the mouse retina. Finally, RNA sequencing of P23H retinal extracts revealed widespread alterations related to the catecholaminergic system during disease progression, including upregulation of the solute carrier family 6 member 2 gene, encoding norepinephrine transporter, and the protein phosphatase 1 regulatory subunit 1B gene, which encodes DA- and cAMP-regulated neuronal phosphoprotein. In conclusion, these data demonstrate elevated DA levels in P23H and rd10 mouse retinas, along with several other biochemical changes in the catecholamine system, suggesting a hyperexcited state in early RP progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.